Curanex Pharmaceuticals (CURX) Competitors

$0.31 -0.01 (-1.65%)

Closing price 05/14/2026 04:00 PM Eastern

Extended Trading

$0.30 -0.01 (-1.94%)

As of 08:06 AM Eastern

CURX vs. NNVC, INMB, GRCE, ADXS, and NXTC

Should you buy Curanex Pharmaceuticals stock or one of its competitors? MarketBeat compares Curanex Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Curanex Pharmaceuticals include NanoViricides (NNVC), INmune Bio (INMB), Grace Therapeutics (GRCE), Ayala Pharmaceuticals (ADXS), and NextCure (NXTC). These companies are all part of the "pharmaceutical products" industry.

How does Curanex Pharmaceuticals compare to NanoViricides?

NanoViricides (NYSE:NNVC) and Curanex Pharmaceuticals (NASDAQ:CURX) are both small-cap pharmaceutical preparations industry companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, media sentiment, analyst recommendations and risk.

NanoViricides is trading at a lower price-to-earnings ratio than Curanex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NanoViricides	N/A	N/A	-$8.29M	-$0.48	N/A
Curanex Pharmaceuticals	N/A	N/A	-$4.22M	-$0.17	N/A

In the previous week, Curanex Pharmaceuticals had 5 more articles in the media than NanoViricides. MarketBeat recorded 6 mentions for Curanex Pharmaceuticals and 1 mentions for NanoViricides. Curanex Pharmaceuticals' average media sentiment score of 1.17 beat NanoViricides' score of 0.65 indicating that Curanex Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NanoViricides	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Curanex Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Curanex Pharmaceuticals' return on equity of -49.10% beat NanoViricides' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NanoViricides	N/A	-87.90%	-78.69%
Curanex Pharmaceuticals	N/A	-49.10%	-47.22%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Curanex Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

10.3% of NanoViricides shares are owned by institutional investors. 3.6% of NanoViricides shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Curanex Pharmaceuticals beats NanoViricides on 7 of the 11 factors compared between the two stocks.

How does Curanex Pharmaceuticals compare to INmune Bio?

INmune Bio (NASDAQ:INMB) and Curanex Pharmaceuticals (NASDAQ:CURX) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, risk and analyst recommendations.

Curanex Pharmaceuticals has lower revenue, but higher earnings than INmune Bio. Curanex Pharmaceuticals is trading at a lower price-to-earnings ratio than INmune Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INmune Bio	$50K	893.09	-$45.93M	-$1.67	N/A
Curanex Pharmaceuticals	N/A	N/A	-$4.22M	-$0.17	N/A

In the previous week, INmune Bio and INmune Bio both had 6 articles in the media. Curanex Pharmaceuticals' average media sentiment score of 1.17 beat INmune Bio's score of 0.34 indicating that Curanex Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
INmune Bio	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Curanex Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Curanex Pharmaceuticals' return on equity of -49.10% beat INmune Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
INmune Bio	N/A	-103.03%	-77.66%
Curanex Pharmaceuticals	N/A	-49.10%	-47.22%

INmune Bio currently has a consensus price target of $8.00, suggesting a potential upside of 376.19%. Given INmune Bio's stronger consensus rating and higher possible upside, research analysts clearly believe INmune Bio is more favorable than Curanex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INmune Bio	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.17
Curanex Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

12.7% of INmune Bio shares are held by institutional investors. 21.0% of INmune Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

INmune Bio beats Curanex Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does Curanex Pharmaceuticals compare to Grace Therapeutics?

Grace Therapeutics (NASDAQ:GRCE) and Curanex Pharmaceuticals (NASDAQ:CURX) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, risk and analyst recommendations.

Grace Therapeutics is trading at a lower price-to-earnings ratio than Curanex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grace Therapeutics	N/A	N/A	-$9.57M	-$0.40	N/A
Curanex Pharmaceuticals	N/A	N/A	-$4.22M	-$0.17	N/A

In the previous week, Curanex Pharmaceuticals had 4 more articles in the media than Grace Therapeutics. MarketBeat recorded 6 mentions for Curanex Pharmaceuticals and 2 mentions for Grace Therapeutics. Curanex Pharmaceuticals' average media sentiment score of 1.17 beat Grace Therapeutics' score of 0.95 indicating that Curanex Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Grace Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Curanex Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Grace Therapeutics' return on equity of -15.58% beat Curanex Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grace Therapeutics	N/A	-15.58%	-14.51%
Curanex Pharmaceuticals	N/A	-49.10%	-47.22%

Grace Therapeutics currently has a consensus price target of $6.00, suggesting a potential upside of 173.97%. Given Grace Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Grace Therapeutics is more favorable than Curanex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grace Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Curanex Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

6.1% of Grace Therapeutics shares are held by institutional investors. 11.1% of Grace Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Grace Therapeutics beats Curanex Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does Curanex Pharmaceuticals compare to Ayala Pharmaceuticals?

Curanex Pharmaceuticals (NASDAQ:CURX) and Ayala Pharmaceuticals (NASDAQ:ADXS) are both small-cap pharmaceutical preparations industry companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

In the previous week, Curanex Pharmaceuticals had 6 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 6 mentions for Curanex Pharmaceuticals and 0 mentions for Ayala Pharmaceuticals. Curanex Pharmaceuticals' average media sentiment score of 1.17 beat Ayala Pharmaceuticals' score of 0.00 indicating that Curanex Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Curanex Pharmaceuticals	Positive
Ayala Pharmaceuticals	Neutral

7.2% of Ayala Pharmaceuticals shares are owned by institutional investors. 0.6% of Ayala Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Ayala Pharmaceuticals' return on equity of 0.00% beat Curanex Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Curanex Pharmaceuticals	N/A	-49.10%	-47.22%
Ayala Pharmaceuticals	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Curanex Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Ayala Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Curanex Pharmaceuticals has higher earnings, but lower revenue than Ayala Pharmaceuticals. Curanex Pharmaceuticals is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Curanex Pharmaceuticals	N/A	N/A	-$4.22M	-$0.17	N/A
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A

Summary

Ayala Pharmaceuticals beats Curanex Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

How does Curanex Pharmaceuticals compare to NextCure?

Curanex Pharmaceuticals (NASDAQ:CURX) and NextCure (NASDAQ:NXTC) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

In the previous week, Curanex Pharmaceuticals had 2 more articles in the media than NextCure. MarketBeat recorded 6 mentions for Curanex Pharmaceuticals and 4 mentions for NextCure. Curanex Pharmaceuticals' average media sentiment score of 1.17 beat NextCure's score of 0.11 indicating that Curanex Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Curanex Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NextCure	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

42.7% of NextCure shares are owned by institutional investors. 11.9% of NextCure shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Curanex Pharmaceuticals' return on equity of -49.10% beat NextCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Curanex Pharmaceuticals	N/A	-49.10%	-47.22%
NextCure	N/A	-186.96%	-124.62%

NextCure has a consensus price target of $23.00, suggesting a potential upside of 124.39%. Given NextCure's stronger consensus rating and higher possible upside, analysts clearly believe NextCure is more favorable than Curanex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Curanex Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NextCure	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Curanex Pharmaceuticals is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Curanex Pharmaceuticals	N/A	N/A	-$4.22M	-$0.17	N/A
NextCure	N/A	N/A	-$55.84M	-$17.19	N/A

Summary

Curanex Pharmaceuticals and NextCure tied by winning 6 of the 12 factors compared between the two stocks.

Get Curanex Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CURX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CURX vs. The Competition

Export

Metric	Curanex Pharmaceuticals	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$8.94M	$935.60M	$4.27B	$12.37B
Dividend Yield	N/A	4.84%	6.42%	5.35%
P/E Ratio	-1.82	1.48	22.80	25.63
Price / Sales	N/A	115.81	158.70	76.59
Price / Cash	N/A	20.07	53.46	56.33
Price / Book	0.78	8.11	36.80	6.97
Net Income	-$4.22M	-$3.91M	$113.55M	$333.62M
7 Day Performance	-4.02%	9.43%	3.83%	1.09%
1 Month Performance	-32.61%	76.62%	5.96%	3.08%
1 Year Performance	N/A	140.55%	17.90%	35.68%

Curanex Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CURX Curanex Pharmaceuticals	1.1888 of 5 stars	$0.31 -1.6%	N/A	N/A	$8.94M	N/A	N/A	N/A	News Coverage Positive News Earnings Report Gap Down
NNVC NanoViricides	0.4152 of 5 stars	$1.72 +14.7%	N/A	+38.1%	$37.14M	N/A	N/A	20
INMB INmune Bio	1.4909 of 5 stars	$1.46 +5.0%	$8.00 +447.9%	-77.4%	$36.95M	$50K	N/A	10	News Coverage Gap Up
GRCE Grace Therapeutics	3.0128 of 5 stars	$2.25 -3.4%	$6.00 +166.7%	-18.9%	$36.05M	N/A	N/A	N/A	Positive News
ADXS Ayala Pharmaceuticals	N/A	$0.60 flat	N/A	N/A	$35.79M	$3.24M	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CURX) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Curanex Pharmaceuticals (CURX) Competitors

CURX vs. NNVC, INMB, GRCE, ADXS, and NXTC

How does Curanex Pharmaceuticals compare to NanoViricides?

Summary

How does Curanex Pharmaceuticals compare to INmune Bio?

Summary

How does Curanex Pharmaceuticals compare to Grace Therapeutics?

Summary

How does Curanex Pharmaceuticals compare to Ayala Pharmaceuticals?

Summary

How does Curanex Pharmaceuticals compare to NextCure?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CURX vs. The Competition

Curanex Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Curanex Pharmaceuticals (CURX) Competitors

CURX vs. NNVC, INMB, GRCE, ADXS, and NXTC

How does Curanex Pharmaceuticals compare to NanoViricides?

Which has stronger earnings and valuation, NNVC or CURX?

Does the media refer more to NNVC or CURX?

Is NNVC or CURX more profitable?

Do analysts prefer NNVC or CURX?

Do insiders & institutionals have more ownership in NNVC or CURX?

Summary

How does Curanex Pharmaceuticals compare to INmune Bio?

Which has higher earnings & valuation, INMB or CURX?

Does the media favor INMB or CURX?

Is INMB or CURX more profitable?

Do analysts prefer INMB or CURX?

Do institutionals & insiders have more ownership in INMB or CURX?

Summary

How does Curanex Pharmaceuticals compare to Grace Therapeutics?

Which has higher earnings & valuation, GRCE or CURX?

Does the media favor GRCE or CURX?

Is GRCE or CURX more profitable?

Do analysts prefer GRCE or CURX?

Do institutionals & insiders have more ownership in GRCE or CURX?

Summary

How does Curanex Pharmaceuticals compare to Ayala Pharmaceuticals?

Does the media prefer CURX or ADXS?

Do insiders and institutionals have more ownership in CURX or ADXS?

Is CURX or ADXS more profitable?

Do analysts recommend CURX or ADXS?

Which has better valuation & earnings, CURX or ADXS?

Summary

How does Curanex Pharmaceuticals compare to NextCure?

Does the media prefer CURX or NXTC?

Do insiders and institutionals have more ownership in CURX or NXTC?

Is CURX or NXTC more profitable?

Do analysts recommend CURX or NXTC?

Which has better valuation & earnings, CURX or NXTC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CURX vs. The Competition

Curanex Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools